Beatrix Stelte‐Ludwig

Author

Bayer (Germany)ORCID

Also Known As

B Stelte-Ludwig, B. Stelte-Ludwig, Beatrix Stelte-Ludwig, Beatrix Stelte‐Ludwig, Hans-Georg Lerchen

143

Publications

895

Citations

H-Index

Concepts

All Affiliations

Bayer (Germany)Bayer (France)Bayer (United States)Bayer (Japan)UCB Pharma (Germany)

About

Beatrix Stelte‐Ludwig is an author at Bayer (Germany) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	184
2	Biochemistry	3	3	66
3	Biomolecular Engineering	2	2	49
4	Cell Biology	2	2	83
5	Engineering	1	1	10

Beatrix Stelte‐Ludwig

Publications

836

Citations

H-Index

Page 1

	Year	Citations
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect Sven Golfier, Charlotte Kopitz, Antje Kahnert, Molecular Cancer Therapeutics	2014	245
Pre‐clinical evidence for the use of phosphodiesterase‐5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms Hanna Tinel, Beatrix Stelte‐Ludwig, Joachim Hütter, British Journal of Urology	2006	156
Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors Anette Sommer, Charlotte Kopitz, Christoph A. Schatz, Cancer Research PathologyTumor BiologyPreclinical EfficacyFibroblast Growth FactorFgfr2 Amplification	2016	73
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models Maria Quanz, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Oncotarget	2018	56
Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer Jörg Willuda, Lars Lindén, Hans‐Georg Lerchen, Molecular Cancer Therapeutics	2017	45
Antibody–Drug Conjugates with Pyrrole‐Based KSP Inhibitors as the Payload Class Hans‐Georg Lerchen, Sven Wittrock, Beatrix Stelte‐Ludwig, Angewandte Chemie International Edition Tumor BiologyDrug TargetNovel TherapyBiochemistryMedicine	2018	39
A Novel NAMPT Inhibitor-Based Antibody–Drug Conjugate Payload Class for Cancer Therapy Niels Böhnke, Markus Berger, Nils Griebenow, Bioconjugate Chemistry	2022	30
Biphenyls as potent vitronectin receptor antagonists Klaus Urbahns, Michael Härter, Markus Albers, Bioorganic & Medicinal Chemistry Letters Functional SelectivityMedicinePharmacotherapyPharmacologyDrug Discovery	2002	25
Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads Hans‐Georg Lerchen, Beatrix Stelte‐Ludwig, Anette Sommer, Bioconjugate Chemistry	2020	22
Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas Klaus Urbahns, Michael Härter, Andrea Vaupel, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyUrologyFunctional SelectivityMedicineBiphenylalanine Ureas	2003	20

Page 1